BR9807471A - Uso do composto anti-cd40l - Google Patents

Uso do composto anti-cd40l

Info

Publication number
BR9807471A
BR9807471A BR9807471A BR9807471A BR9807471A BR 9807471 A BR9807471 A BR 9807471A BR 9807471 A BR9807471 A BR 9807471A BR 9807471 A BR9807471 A BR 9807471A BR 9807471 A BR9807471 A BR 9807471A
Authority
BR
Brazil
Prior art keywords
cd40l compound
cd40l
compound
immune
weeks
Prior art date
Application number
BR9807471A
Other languages
English (en)
Portuguese (pt)
Inventor
Susan Kalled
David W Thomas
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR9807471A publication Critical patent/BR9807471A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9807471A 1997-01-10 1998-01-09 Uso do composto anti-cd40l BR9807471A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3467297P 1997-01-10 1997-01-10
US4015497P 1997-03-07 1997-03-07
PCT/US1998/000573 WO1998030241A1 (en) 1997-01-10 1998-01-09 Methods of therapeutic administration of anti-cd40l compounds

Publications (1)

Publication Number Publication Date
BR9807471A true BR9807471A (pt) 2000-03-21

Family

ID=26711241

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807471A BR9807471A (pt) 1997-01-10 1998-01-09 Uso do composto anti-cd40l

Country Status (20)

Country Link
US (2) US20020071840A1 (https=)
EP (1) EP0966302B1 (https=)
JP (1) JP2001508450A (https=)
KR (2) KR20000070035A (https=)
CN (1) CN1248921A (https=)
AT (1) ATE356634T1 (https=)
AU (1) AU721697B2 (https=)
BR (1) BR9807471A (https=)
CA (1) CA2277223A1 (https=)
CZ (1) CZ244399A3 (https=)
DE (1) DE69837322T2 (https=)
EA (1) EA001426B1 (https=)
EE (1) EE9900275A (https=)
IL (1) IL130785A0 (https=)
IS (1) IS5101A (https=)
NO (1) NO993275L (https=)
NZ (1) NZ337073A (https=)
PL (1) PL193966B1 (https=)
TR (1) TR199902192T2 (https=)
WO (1) WO1998030241A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
BR9809641A (pt) * 1997-05-17 2000-07-11 Biogen Inc Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto
CN1261285A (zh) * 1997-06-20 2000-07-26 拜奥根有限公司 治疗性蛋白抑制剂综合症的cd154阻断治疗
NZ511034A (en) * 1998-09-21 2004-03-26 American Nat Red Cross Methods of downmodulating the immune response to therapeutic proteins
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
WO2001066141A1 (fr) * 2000-03-06 2001-09-13 Eisai Co., Ltd. Agents therapeutiques et prophylactiques diriges contre le syndrome des antiphospholipides
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
CA2781858C (en) 2000-05-12 2015-03-31 Genzyme Corporation Modulators of tnf-.alpha. signaling
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
ATE520400T1 (de) * 2002-11-21 2011-09-15 Genzyme Corp Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
EP2367849B1 (en) 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
WO2025117849A1 (en) 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235683A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
ES2143553T3 (es) * 1993-09-02 2000-05-16 Dartmouth College Anticuerpos anti-gp39 y sus utilizaciones.
NZ273208A (en) * 1993-09-02 2000-12-22 Dartmouth College Suppressing a humoral immune response against a thymus dependant (TD) antigen
ES2222463T3 (es) * 1993-12-23 2005-02-01 Immunex Corporation Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos.
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
US20050158314A1 (en) 2005-07-21
CA2277223A1 (en) 1998-07-16
KR20050088494A (ko) 2005-09-06
CZ244399A3 (cs) 1999-10-13
CN1248921A (zh) 2000-03-29
PL334500A1 (en) 2000-02-28
EE9900275A (et) 2000-02-15
KR100632846B1 (ko) 2006-10-16
WO1998030241A1 (en) 1998-07-16
AU721697B2 (en) 2000-07-13
DE69837322D1 (de) 2007-04-26
EA001426B1 (ru) 2001-02-26
DE69837322T2 (de) 2007-11-22
KR20000070035A (ko) 2000-11-25
JP2001508450A (ja) 2001-06-26
EP0966302B1 (en) 2007-03-14
AU5735398A (en) 1998-08-03
US20020071840A1 (en) 2002-06-13
HK1024424A1 (en) 2000-10-13
PL193966B1 (pl) 2007-04-30
TR199902192T2 (xx) 1999-12-21
EP0966302A1 (en) 1999-12-29
EA199900633A1 (ru) 2000-02-28
IS5101A (is) 1999-06-30
NZ337073A (en) 2001-01-26
IL130785A0 (en) 2001-01-28
NO993275D0 (no) 1999-07-01
ATE356634T1 (de) 2007-04-15
NO993275L (no) 1999-09-09

Similar Documents

Publication Publication Date Title
BR9807471A (pt) Uso do composto anti-cd40l
BR9902086A (pt) Formulações farmacêuticas.
DK0999749T3 (da) Formuleringer med høj koncentration af ammoniumglyphosat
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
DZ3191A1 (fr) Composés d'indazole et compositions pharmaceutiques inhibant les protéines kinases, et procédés d'utilisation de ceux-ci.
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
BR9806752A (pt) Ftalazinonas.
BR9908280A (pt) Inibidores de enzimas de fosfolipase
DE69926686D1 (de) Vorrichtung zur Verabreichung von hochkonzentrierten NO Pulsen
EE9900539A (et) Uued ühendid
DK1021194T3 (da) Ny forbedret formulering til behandling af osteoporose
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
BR9813228A (pt) Formulação de 2-metil-tieno-benzodiazepina
DE69330733D1 (de) 9-[(Substituierte Glycyl)amido]-6-demethyl-6-deoxytetracycline als antibiotische Mittel
DE69942708D1 (de) Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
TR199900310T2 (xx) Trombin inhibit�rleri
ID26400A (id) Alat dan metode pengoreksi kesalahan bentuk luar
DE69731646D1 (de) Verabreichung von nukleinsäurepartikeln
IT1282627B1 (it) Procedimento per la preparazione di perfluoropoliossialchileni perossidici
BR9704595A (pt) Preparação de 3-amino-1-hidroxipropano-1, 1-ácido difosfõnico
IS5906A (is) Sertralín efnisthykkni til gjafar um munn
EA200000112A1 (ru) Новая композиция
NO981340L (no) Stabiliserte fosfolipidsammensetninger
ITMI981796A0 (it) Procedimento per la preparazione di r-(-)-carnitina

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA, INC. (US)

Free format text: ALTERADO DE: BIOGEN, INC.

B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA INC. (US)

Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA (ART. 8O CPMBINADO COM ART. 13 DA LPI ) E NAOE CONSIDERADO INVENCAO, UMA VEZ QUE INCIDE NO ART. 10 ( INCISO VIII ) DA LPI.